Wyeth is introducing Pristiq (desvenlafaxine 50 mg and 100 mg extended-release tablets) for the symptomatic relief of major depressive disorder in adults.
Novartis' Aclasta (zoledronic acid injection) is now approved for use as a once-yearly intravenous (IV) infusion in the prevention and treatment of corticosteroid-induced osteoporosis, to increase bone mineral density.
